Merck Medicine - Search News

Merck licenses Chinese cancer drug

Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from LaNova Medicines, a Shanghai-based firm, for $588 million upfront and as much as $2.7 billion in potential milestone payments.

Reuters on MSN · 9h

Merck signs up to $3.3 billion cancer drug deal with China-based LaNova

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday. The deal allows Merck to take over development of LaNova's LM-299,

Bloomberg L.P. · 9h

Merck Snags Chinese Cancer Drug in Deal Worth Up to $3.3 Billion

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront, plus as much as $2.7 billion in milestone payments.

Masimo to Present in Jefferies London Healthcare Conference

Business Wire · 8d

Merck to Participate in the UBS Global Healthcare Conference

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, Human Health U.S., and Dr. Joerg Koglin, senior vice president and head of general medicine,

Business Insider · 8h

Solid Biosciences to Present at the Jefferies London Healthcare Conference

Institutional investors interested in meeting with management during the conference may reach out to their Jefferies representatives. About Solid Biosciences Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne),

Masimo to Present in the Jefferies London Healthcare Conference

Masimo (NASDAQ: MASI) today announced that its management will participate in the Jefferies London Healthcare Conference on Thursday, November 21, 2024 at 8:30 a.m. GMT. A live webcast of the presentation will be available on the Masimo website at A replay of the webcast will be available following the live presentation.

5h

Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

Yale Daily News19h

Yale spin-off company Modifi Bio acquired by Merck in multimillion dollar deal

Merck was founded in 1668 and is the world’s oldest operating chemical and pharmaceutical company. Asuka Koda covers the ...

2h

Merck KGaA (MKGAF) Q3 2024 Earnings Call Transcript

Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor ...

12h

Merck Foundation Marking "World Diabetes Day" by Providing out of 2080 Scholarships, 830 Scholarships for Diabetes and Hypertension in 52 Countries

BusinessWire India Accra [Ghana] Mumbai Maharashtra [India] November 14 Merck Foundation the philanthropic arm of Merck KGaA ...

Ginkgo Bioworks advances collaboration with Merck to improve Biologics manufacturing

Boston: Ginkgo Bioworks has announced the completion of the first milestone of a previously announced partnership with ...

2d

Merck KGaA: Phase III Trial Of Pimicotinib In Tenosynovial Giant Cell Tumor Meets Primary Endpoint

Merck KGaA (MKGAY.PK), a German science and technology major, announced that the Phase III MANEUVER trial of pimicotinib, an ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results